Literature DB >> 15590126

Influence of mistletoe lectins and cytokines induced by them on cell proliferation of human melanoma cells in vitro.

Anka Thies1, Dirk Nugel, Uwe Pfüller, Ingrid Moll, Udo Schumacher.   

Abstract

Although aqueous mistletoe extracts are widely used in complementary cancer therapy, the precise mode of action of their main therapeutic agents, the three mistletoe lectins (MLs), is poorly understood as they act both as cytotoxic agents and as immunomodulators due to their cytokine release by mononuclear cells. Thus, this study aims to investigate both the direct and the indirect effects of MLs on the growth of human melanoma cells in vitro. Proliferation of six human melanoma cell lines under ML treatment and additionally under the influence of cytokines induced by them (TNF-alpha, IL-1, IL-6) was assessed by means of the tetrazolium derived reduction (XTT) assay. Furthermore, ML binding patterns were analysed and correlated with the biological effects. All three MLs inhibited melanoma cell proliferation in a dose-dependent manner starting at very low ML concentrations (0.001-100 ng/ml) with ML-I being the most cytotoxic lectin (significant inhibition of ultra-sensitive cell line MV3 at 1 x 10(-13) ng ML-I/ml). Even if applied in a broad concentration range (0.0001-100 ng/ml) cytokines had no influence on cell proliferation at all. For ML-I, no association between binding intensity and cytotoxicity was observed, while for ML-II and -III an association between binding and toxicity was established. In conclusion, this study emphasises the direct anti-proliferative effect of the mistletoe lectins on melanoma cells with ML-I being superior to MLs-II and -III. The observation of an ultra-sensitivity of one cell line towards ML-I toxicity may serve as an explanation for the therapeutic success in anecdotal case reports and needs further investigations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15590126     DOI: 10.1016/j.tox.2004.09.009

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  14 in total

1.  Direct targeting of cancer cells: a multiparameter approach.

Authors:  Eileen L Heinrich; Lily Anne Y Welty; Lisa R Banner; Steven B Oppenheimer
Journal:  Acta Histochem       Date:  2005-09-21       Impact factor: 2.479

2.  Analysis of unconventional approaches for the rapid detection of surface lectin binding ligands on human cell lines.

Authors:  Lily Anne Y Welty; Eileen L Heinrich; Karina Garcia; Lisa R Banner; Michael L Summers; Larry Baresi; Stan Metzenberg; Cathy Coyle-Thompson; Steven B Oppenheimer
Journal:  Acta Histochem       Date:  2006-01-18       Impact factor: 2.479

Review 3.  A glycobiology review: carbohydrates, lectins and implications in cancer therapeutics.

Authors:  Haike Ghazarian; Brian Idoni; Steven B Oppenheimer
Journal:  Acta Histochem       Date:  2010-03-02       Impact factor: 2.479

4.  Active Chinese mistletoe lectin-55 enhances colon cancer surveillance through regulating innate and adaptive immune responses.

Authors:  Yan-Hui Ma; Wei-Zhi Cheng; Fang Gong; An-Lun Ma; Qi-Wen Yu; Ji-Ying Zhang; Chao-Ying Hu; Xue-Hua Chen; Dong-Qing Zhang
Journal:  World J Gastroenterol       Date:  2008-09-14       Impact factor: 5.742

5.  A calcium ion-dependent dimeric bean lectin with antiproliferative activity toward human breast cancer MCF-7 cells.

Authors:  Randy Chi Fai Cheung; Ho Him Leung; Wen Liang Pan; Tzi Bun Ng
Journal:  Protein J       Date:  2013-03       Impact factor: 2.371

Review 6.  Safety of higher dosages of Viscum album L. in animals and humans--systematic review of immune changes and safety parameters.

Authors:  Gunver S Kienle; Renate Grugel; Helmut Kiene
Journal:  BMC Complement Altern Med       Date:  2011-08-28       Impact factor: 3.659

7.  Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer.

Authors:  Anja Thronicke; Megan L Steele; Christian Grah; Burkhard Matthes; Friedemann Schad
Journal:  BMC Complement Altern Med       Date:  2017-12-13       Impact factor: 3.659

8.  Quantitative analysis of receptor-mediated uptake and pro-apoptotic activity of mistletoe lectin-1 by high content imaging.

Authors:  N Beztsinna; M B C de Matos; J Walther; C Heyder; E Hildebrandt; G Leneweit; E Mastrobattista; R J Kok
Journal:  Sci Rep       Date:  2018-02-09       Impact factor: 4.379

9.  Triterpenoids amplify anti-tumoral effects of mistletoe extracts on murine B16.f10 melanoma in vivo.

Authors:  Christian M Strüh; Sebastian Jäger; Astrid Kersten; Christoph M Schempp; Armin Scheffler; Stefan F Martin
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

10.  Low-dose mistletoe lectin-I reduces melanoma growth and spread in a scid mouse xenograft model.

Authors:  A Thies; P Dautel; A Meyer; U Pfüller; U Schumacher
Journal:  Br J Cancer       Date:  2007-11-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.